27 recruiting, 14 not yet recruiting, 5 active not recruiting, 2 completed. 25 Phase 2, 7 Phase 1, 4 Phase 3, 3 Not applicable, 2 Early Phase 1.
Follow DLBCL - Diffuse Large B Cell Lymphoma: new trials by email Literature Review of DLBCL - Diffuse Large B Cell Lymphoma trials Research Report on DLBCL - Diffuse Large B Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement pirtobrutinib+MTX+immunolchemotherapy - Pirtobrutinib, Immunochemotherapy | Phase 2 | Not yet recruiting | Pengpeng Xu | 24 | 2026-09-01 | 2026-09-11 |
| Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma Pirtobrutinib, Sotoclax+/- Obinutuzumab (PSO) Combination for B cell lymphoma - DLBCL - Diffuse Large B Cell Lymphoma, Richter Transformation | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 40 | 2026-08-30 | 2026-08-06 |
| Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL Orelabrutinib Combined with Pola-R-CHP Regimen - DLBCL - Diffuse Large B Cell Lymphoma, Intermediate-High Risk | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2026-08-30 | 2026-08-21 |
| Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL Pirtobrutinib+Pola-R-CHP - DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 48 | 2026-07-31 | 2026-08-06 |
| Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL Pirtobrutinib plus R-CHOP - DLBCL - Diffuse Large B Cell Lymphoma, R-CHOP Chemotherapy | Phase 2 | Not yet recruiting | Changzhou No.2 People's Hospital | 34 | 2026-07-30 | 2026-08-06 |
| Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL hypofractionated radiotherapy plus GM-CSF, pomalidomide and glofitamab - DLBCL - Diffuse Large B Cell Lymphoma, PCNSL (Primary CNS Lymphoma) | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 53 | 2026-07-25 | 2026-08-06 |
| Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma R-CHOP+Orelabrutinib, POLA-R-CHP+orelabrutinib, R-miniCHOP +orelabrutinib - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ou Bai, MD/PHD | 66 | 2026-06-16 | 2026-07-01 |
| A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma SCTB35 injection, Rituxumab, Gemcitabine - DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | Sinocelltech Ltd. | 101 | 2026-06-04 | 2026-08-13 |
| Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP CL-Pola-R-CHP - DHL, THL | Phase 2 | Not yet recruiting | Ruijin Hospital | 28 | 2026-05-01 | 2026-04-27 |
| A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma CT1182 injection - B-cell Non Hodgkin Lymphoma (NHL), DLBCL - Diffuse Large B Cell Lymphoma | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2026-04-30 | 2026-04-23 |
| Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma MDX2003 - Lymphoma, Waldenström Macroglobulinemia (WM) | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 180 | 2026-04-13 | 2026-11-06 |
| A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping C-Pola-R-CHP+X, CR-CHOP - DLBCL - Diffuse Large B Cell Lymphoma, Double Expressor Lymphoma | Phase 3 | Not yet recruiting | Ruijin Hospital | 156 | 2026-03-31 | 2026-04-06 |
| Modified DHAP Versus Standard DHAP in Relapsed/Refractory Diffused Large B-cell Lymphoma. Cisplatin (modified schedule), Cisplatin, Dexametasone - DLBCL - Diffuse Large B Cell Lymphoma | Phase 3 | Recruiting | King Edward Medical University | 74 | 2026-03-18 | 2026-08-10 |
| Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma DLBCL - Diffuse Large B Cell Lymphoma | Not yet recruiting | Henan Cancer Hospital | 20 | 2026-03-10 | 2026-03-16 | |
| Glofitamab Combined With CAR-T Therapy in R/R DLBCL Glofitamab, Obinutuzumab, Axicabtagene Ciloleucel - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 24 | 2026-03-01 | 2026-01-08 |
| Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) Orelabrutinib combined with standard immunochemotherapy with or without auto-HSCT - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Recruiting | The Affiliated Hospital of Xuzhou Medical University | 30 | 2026-03-01 | 2026-07-02 |
| Long-term Study to Evaluate Safety and Persistence of GF-CART01 DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma (FL) | Enrolling by invitation | GenomeFrontier Therapeutics TW Co., Ltd. | 18 | 2026-02-26 | 2026-06-11 | |
| Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL Rituximab+Ifosfamide+Mesna+Mitoxantrone hydrochloride liposome+Etoposide, Rituximab+Gemcitabine+Oxaliplatin - DLBCL - Diffuse Large B Cell Lymphoma | Not applicable | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 70 | 2026-02-25 | 2026-02-05 |
| This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma LTZ-301 - Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | LTZ Therapeutics, Inc. | 42 | 2026-01-29 | 2026-07-24 |
| Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma Glofitamab; Polatuzumab vedotin; Zuberitamab; Cyclophosphamide; Doxorubicin; Prednisone - DLBCL - Diffuse Large B Cell Lymphoma, Chemo-free Therapy | Phase 2 | Not yet recruiting | Li Zhiming | 40 | 2026-01-15 | 2025-11-19 |
Showing 20 of 50. Sign in to see all of them.
Dendritic Cell Sarcoma, Interdigitating (50) · Lymphoma, Follicular (8) · Lymphoma, Large B-Cell, Diffuse (8) · Lymphoma, B-Cell (6) · Lymphoma (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Non-Hodgkin (3) · Recurrence (3) · Lymphoma, Mantle-Cell (2) · Waldenstrom Macroglobulinemia (2) · Breast Neoplasms (1) · Cardiotoxicity (1) · Colorectal Neoplasms (1) · Heart Failure (1) · Leukemia, B-Cell (1)
Hemic and Lymphatic Diseases (50) · Histiocytic Disorders, Malignant (50) · Histiocytosis (50) · Lymphatic Diseases (50) · Neoplasms (50) · Neoplasms by Histologic Type (50) · Immune System Diseases (19) · Immunoproliferative Disorders (19) · Lymphoproliferative Disorders (19) · Lymphoma (16) · Lymphoma, Non-Hodgkin (15) · Lymphoma, B-Cell (8) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Cardiovascular Diseases (3)
Cyclophosphamide (6) · Doxorubicin (5) · Rituximab (5) · glofitamab (5) · Prednisone (4) · polatuzumab vedotin (4) · pirtobrutinib (3) · Azacitidine (2) · Vincristine (2) · obinutuzumab (2) · orelabrutinib (2) · Absorptiometry, Photon (1) · Automobiles (1) · Cisplatin (1) · Cytarabine (1)
Ruijin Hospital (4) · The First Affiliated Hospital of Xiamen University (4) · Changzhou No.2 People's Hospital (3) · Memorial Sloan Kettering Cancer Center (2) · The First Affiliated Hospital with Nanjing Medical University (2) · Abramson Cancer Center at Penn Medicine (1) · Ain Shams University (1) · Athenex, Inc. (1) · Australasian Leukaemia and Lymphoma Group (1) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · GenomeFrontier Therapeutics TW Co., Ltd. (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Henan Cancer Hospital (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Incyte Biosciences Italy S.r.l (1)
China (22) · United States (10) · Italy (3) · Australia (2) · Netherlands (2) · Austria (1) · Canada (1) · Egypt (1) · France (1) · Germany (1) · Israel (1) · Japan (1) · Pakistan (1) · Spain (1) · Taiwan (1)
A. van Rhenen, MD (1) · Alice Di Rocco (1) · Bing Xu (1) · Bing Xu, PhD (1) · Bing Xu, PhD，MD (1) · Bruce Hough, MD (1) · Carlos Ramos, MD (1) · Christopher R D'Angelo, MD (1) · Doaa A Mohamed, MD (1) · Inbsaat Iqbal, MBBS, MD (1) · Jennifer Lue, MD (1) · Jinhua Liang (1) · Juan Alderuccio, MD (1) · Kelly McConnell, PhD (1) · Laura A Johnson, PhD (1)
PMID 23235801, PMID 39875951, PMID 42285114
2023 (1)